Abstract: METHODS: We extracted all subtype B HIV-1 pol gene sequences from treatment-naive patients within the United Kingdom HIV Drug Resistance Database sampled between 1997 and 2011 and carrying the most common protease inhibitors, nonnucleoside and nucleotide reverse transcriptase inhibitors TDR mutations, namely, L90M, K103N, and T215Y/F/rev, respectively (n = 1140).
Analysis of the Zidovudine Resistance Mutations T215Y, M41L, and L210W in HIV-1 Reverse Transcriptase.
PMID: 26324274
2015
Antimicrobial agents and chemotherapy
Abstract: The primary resistance pathway selects for mutations of T215 that change the threonine to either a tyrosine or a phenylalanine (T215Y/F); this resistance pathway involves an ATP-dependent excision mechanism.
HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.
Result: Fig 2 shows that in viruses from individuals in LMICs with intermediate or high-level NRTI resistance following VF on a first-line NRTI/NNRTI-containing regimen, the most common major DRMs were M184V (91.5%) and M184I (3.7%), K
Figure: Major NRTI-associated DRMs (HIVDB score >=30) included K65R, D67 deletion, T69 insertion, K70R, L74V/I, Y115F, Q151M, M184I/V, and T215F/Y.
Outcome of patients on second line antiretroviral therapy under programmatic condition in India.
Result: In the reverse transcriptase gene, the T215F mutation was significantly more selected in non-B subtypes (p = 0.023).
Result: Taking into account multiple mutations together, the thymidine analog mutations (TAM) pathway 1 (including M41L, L210W, and T215Y) was selected in 40.8% of the patients, whereas TAM-2 (including D67N, K70R, T215F, and 58 K219Q/E) was present in 42.2%.
Result: The most prevalent mutations related to NRTIs were M184V (80.1%), followed by M41L (31.8%), T215Y (30.2%), D67N
Assessing transmissibility of HIV-1 drug resistance mutations from treated and from drug-naive individuals.
Figure: T215Y/F and T215Rev are shown in green but were taken together (T215) for the linear regression.
Discussion: T215Rev and T215Y/F are above and below the regression line respectively, supporting our model, as T215Y/F has a fitness cost in absence of drug and reverts after transmission into one of the T215Rev mutants with less onward transmission of T215Y/F between drug-naive patients.
Discussion: We show here that D30N, N88D/S and L90 M also have high transmissibility and that other SDRMs have higher (M41L, T215Rev and K219E/N/Q/R for NRTIs and K10
Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia.
Discussion: Despite the extensive use of thymidine analogues like AZT or D4T in Ethiopia and unlike previous similar studies, TAMs characterized by the mutations M41L, L210W, T215Y (TAM-path 1) and D67N, K70R, T215F, K219Q/E (TAM-path 2) were lacking in the current study indicating a recent period of virological failure.
Longitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage Therapy.
Abstract: According to ARV used in these individuals, we focused on the following seven reverse transcriptase inhibitor-resistant mutations: M41L, K65R, K70R, K103N, Y181C, M184V, and T215F/Y.
Introduction: In this study, we used AS-PCR to analyze expression dynamics of eight drug resistance mutations (M41L, K65R, K70R, K103N, Y181C, M184V and T215F/Y) during the clinical course of ARV-treated individua
HIV mutation literature information.
PMID: 
2015
Clinical infectious diseases
Browser Board
Co-occurred Entities
Filtrator
ViMRT